Weight gain · women with chronic pelvic pain
Medical treatment leads to higher weight gain: progesterone versus placebo compared with placebo (high certainty).
1 finding from 1 review
Bloatedness: progesterone versus placebo · women with chronic pelvic pain
Medical treatment leads to higher bloatedness: progesterone versus placebo compared with placebo (high certainty).
1 finding from 1 review
Peto OR 3.2 [1.37, 7.47]
85 participants
High
Incontinent episodes over 24 hours ‐ oestrogen + progesterone vs placebo · patients with urinary incontinence in post‐menopausal women
1 finding from 1 review
Number with incontinence not improved (women's observations) ‐ oestrogen + progesterone vs placebo (Copy) · patients with urinary incontinence in post‐menopausal women
Oestrogen + other treatments leads to higher number with incontinence not improved (women's observations) ‐… compared with placebo (high certainty).
1 finding from 1 review
Maternal infection or inflammation · women with singleton pregnancies at risk of cervical insufficiency
Cervical pessary showed no clear difference in maternal infection or inflammation compared with vaginal progesterone (moderate certainty).
1 finding from 1 review
Neonatal/paediatric care unit admission · women with singleton pregnancies at risk of cervical insufficiency
Cervical pessary showed no clear difference in neonatal/paediatric care unit admission compared with vaginal progesterone (low certainty).
1 finding from 1 review
Fetal/infant mortality · women with singleton pregnancies at risk of cervical insufficiency
Cervical pessary showed no clear difference in fetal/infant mortality compared with vaginal progesterone (low certainty).
1 finding from 1 review
Harm to offspring from the intervention · women with singleton pregnancies at risk of cervical insufficiency
1 finding from 1 review
Birthweight (g) · women with singleton pregnancies at risk of cervical insufficiency
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Preterm birth less than 34 weeks' gestation · women with singleton pregnancies at risk of cervical insufficiency
Cervical pessary showed no clear difference in delivery before 34 weeks' gestation compared with vaginal progesterone (moderate certainty).
1 finding from 1 review
Preterm birth · women with singleton pregnancies at risk of cervical insufficiency
Cervical pessary showed no clear difference in delivery before 37 weeks' gestation compared with vaginal progesterone (moderate certainty).
1 finding from 1 review
MBL (mL per cycle) · women with heavy menstrual bleeding
1 finding from 1 review
Number of days' bleeding · women with heavy menstrual bleeding
1 finding from 1 review
Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Regression rate at 6 months · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Nausea · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
1 finding from 1 review
Prevalence of dysmenorrhoea · women with symptomatic endometriosis
Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).
1 finding from 1 review
Side effects ‐ hot flushes · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes side effects: hot flushes compared with danazol (very low certainty).
1 finding from 1 review
Adverse effects: acne · women with symptomatic endometriosis
Gestrinone showed no clear difference in side effects: acne compared with danazol (low certainty).
1 finding from 1 review